Starling Oncology, Inc.

Starling Oncology, Inc.

STLN - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$3.14B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Starling Oncology, Inc.Starling Oncology, Inc.-12.1-95%--0.7
$9.00

Target Price by Analysts

200% upsideStarling Oncology Target Price DetailsTarget Price
$-6.05

Current Fair Value

301.6% downside

Overvalued by 301.6% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$3.14 Billion
Enterprise Value$3.13 Billion
Earnings per Share$-0.54
Beta0.42
Outstanding Shares1,047,283,900

Return

Return on Equity95.13%ROE
Return on Assets-18.93%
Return on Invested Capital-37.98%

Valuation & Multiples

P/E Ratio-12.07P/E Ratio
PEG263.47PEG
Price to Sales-Price to Sales
Price to Book Ratio-3.0Price to Book Ratio
Enterprise Value to Revenue5.05
Enterprise Value to EBIT-128.64
Enterprise Value to Net Income-89
Total Debt to Enterprise0.01
Debt to Equity-0.67Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 5, 2026
EPS
-$0.13
Est. -$0.05
Revenue
$169.77 M
Est. $168.68 M

Next Earnings Call

Expected Date
March 11, 2027
EPS Estimate
-$0.04
Consensus analyst estimate
Revenue Estimate
$177.90 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About DFP Healthcare Acquisitions Corp

641 employees
CEO: Daniel Virnich

DFP Healthcare Acquisitions Corp. is a blank check company. The Company’s business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more ...

Starling Oncology Insider Information FAQ

Stockcircle shows 1 open-market insider purchase and 2 open-market insider sales for Starling Oncology in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Stockcircle lists 12 politician trade disclosures tied to Starling Oncology in the last twelve months, drawn from periodic financial disclosure reports. 1 politician traded Starling Oncology in the past year.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.

Questions & Answers